Sana Kamal

• Leading Malaysia and Singapore Patient Solutions team to grow the business with pharmaceutical client
• Developed innovative programs based on therapy and client needs to bring access to patients
• Managing 15 Patient Support Program including access, adherence and convenience programs
• Built and developed SOPs, country teams in markets to ensure adherence to regulations and workflows
• Lead pricing and contract negotiation activities with prospective clients
• Managed operating budgets and costs
• Managed cross functional collaboration to drive effectiveness

• Built quality system in Vietnam to operationalise digital Patient Support Programs
• Migrated manual Patient Support Programs to digital solution
• Lead In depth analytics of patient trends to understand patient drop outs and program success
• Built team capabilities to manage digital programs and adhere to Standard Operating Procedures and Work Instructions
• Regular risk assessment of programs that undergo changes to ensure program meets local regulatory requirements
• Standardized program application process to ensure faster submissions and approvals of Patient Access Programs by Ministry of Health
• Ensured timely execution of project from project signing to go-live to continuous monitoring

• Identified emerging markets by analyzing demographic data, enabling targeted marketing efforts for increased revenue growth.
• Conducted segmentation analysis to better understand target audiences, informing tailored messaging strategies that resonate effectively.
• Researched and evaluated potential new markets and products.
• Generated reports to support development and implementation of marketing plans.

• Researched on payer willingness and motivators for reimbursement
• Mapped pay for performance models operational in disease area
• Co-facilitated stakeholder discussions/focus groups related to value based care models

Propose strategies for Novartis to increase access for privately insured patients to specialty medicines based on

• Mapping out overall healthcare financing landscape in Singapore
• Evolution of private health insurance, key trends, drivers and projection for the next 5 years
• Private health insurance criteria for drug decision making and principles of policy design
• Key decision makers & influencers in private health insurance

• Successful completion of transfer of all registrations and licenses as part of legal entity change
• Prepared registration dossiers and submission with Central and State Licensing authorities for imported and locally manufactured products
• Country point of contact for regional and global regulatory affairs teams to ensure efficient internal collaboration while compiling dossiers for submissions
• Compiled Modules of the CTD dossier (Module 1 to Module 5)

• Ensured compliance to regulatory, medical information and Pharmacovigilance requirements related to drug safety as per EMEA guidelines
• Revised and approved the scientific documents for marketed products such as SPCs, PILs in compliance with the PSUR guidance & information received from MHRA
• Close coordination with PV partner for timely reporting of adverse events and PSUR compilation

• Compilation, scrutiny and examination of dossiers pertaining to WHO GMP certification, Drug registrations & licenses, New drug approvals, BA/BE studies, Central Licensing Authority Approvals
• Site inspections/audits of Manufacturing Units, CRO’s, Blood Banks & Analytical testing labs